The TLC-ART team traveled to Munich to participate in the well-known AIDS IAS conference, where they presented four posters. A highlight of the conference was the positive results from studies on long-acting lenacapavir, administered every six months, which showed promise in preventing HIV transmission.
Given the widespread interest in long-acting treatments, our posters attracted considerable attention from professionals, physicians, and users, leading to several engaging discussions.
Rachel presented preliminary Phase 1 pharmacokinetic and safety data for product 101 (lopinavir/ritonavir/tenofovir), demonstrating the platform’s capabilities.
Zach highlighted how our nano formulation platform can effectively load TAF with 3TC and DTG, a notable achievement since TAF has not been successful as a subcutaneous treatment option.
Simone showcased a method for scaling long-acting injectables with various combinations to design pediatric regimens. By using modeling, we can determine less toxic dosages for equivalent exposure in humans, taking into account metabolism, organ maturation, and the development of the lymphatic system, which influences our nanoparticle pharmacokinetics.
For more info: tlcart@uw.edu